Truist raises Nurix stock price target to $34 on Roche deal
Truist has raised its price target on Nurix Therapeutics to $34, citing the company's deal with Roche as a catalyst. The PT lift frames a potential re-rating moment, but the stock remains deeply unprofitable with a -314.9% net margin, so execution risk is real.
What happened
Truist has raised its price target on Nurix Therapeutics to $34, citing the company's deal with Roche as a catalyst.
The read · Jul 10
NRIX sits between a meaningful Roche deal validation and deep ongoing losses — the question is whether Truist's $34 PT marks a floor or a stretch target ahead of clinical catalysts.
Wrong if
Any negative clinical data on NRX-0492 or other pipeline assets would unwind the Roche-deal premium quickly, and sustained cash burn at current levels risks dilutive equity raises that pressure the share price.
CoverageSource: Investing.com · Published here FRI, JUL 10 · 9:54 AM ET · the only report in this recordHow this is decided →
The chart · NRIXTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
Truist raised its price target on Nurix Therapeutics (NRIX) to $34, driven by the company's collaboration deal with Roche — a meaningful de-risking event for a clinical-stage biotech that posted $84M in revenue (+54% YoY) but still burned at a -314.9% net margin for the fiscal year ending November 2025.
The Roche partnership is the key narrative here: large-pharma validation and potential milestone payments can extend runway and shift the market's perception of pipeline quality. For a company running a diluted EPS of -$3.05, non-dilutive capital and a high-profile collaborator matter.
The bull case is straightforward — if Roche's backing accelerates NRX-0492 or other DEG targets toward readouts, NRIX could see multiple expansion and additional analyst upgrades pile in behind Truist's move. The bear case is equally grounded: at a $34 target, the stock still demands significant faith in pipeline milestones that haven't materialized yet, and the deep losses mean any clinical setback hits an already-thin floor.
The key watch items are whether other sell-side desks follow Truist's upgrade, upcoming clinical data readouts that would validate the Roche thesis, and the rate at which operating cash burn narrows as partnership economics kick in. Until then, this is a conviction call on deal quality, not on fundamentals.
The read, in fullWhy it matters
The Roche deal provides non-dilutive capital and large-pharma validation for Nurix's DEG platform, and Truist's $34 PT implies meaningful upside if additional analysts re-rate. Revenue growth of 54% YoY shows the collaboration economics are beginning to land, even if profitability remains distant at -314.9% net margins.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written
Next · what would move this
4-8 weeks, into next clinical update. Follow to be told when one lands.
▲ The case it holds
Roche's collaboration provides large-pharma credibility and potential near-term milestone payments that could narrow the cash burn gap while Truist's $34 PT leaves meaningful room for further re-rating if peers follow suit.
▼ The case it breaks
With diluted EPS at -$3.05 and net margins of -314.9%, the $34 PT is essentially a pure pipeline call — any clinical stumble or milestone delay in the Roche program removes the primary upside driver with no fundamental earnings floor to catch the stock.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →